Dexmedetomidine versus standard care sedation with propofol or midazolam in intensive care: an economic evaluation.

ABSTRACT:

Introduction

Dexmedetomidine was shown in two European randomized double-blind double-dummy trials (PRODEX and MIDEX) to be non-inferior to propofol and midazolam in maintaining target sedation levels in mechanically ventilated intensive care unit (ICU) patients. Additionally, dexmedetomidine shortened the time to extubation versus both standard sedatives, suggesting that it may reduce ICU resource needs and thus lower ICU costs. Considering resource utilization data from these two trials, we performed a secondary, cost-minimization analysis assessing the economics of dexmedetomidine versus standard care sedation.

Methods

The total ICU costs associated with each study sedative were calculated on the basis of total study sedative consumption and the number of days patients re

SUBMITTER: Turunen H 

PROVIDER: S-EPMC4391080 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature